Home › NDC Lookup › RxCUI directory › RxCUI 2594978

2 ML cabotegravir 200 MG/ML Injection — RxCUI 2594978

Name: 2 ML cabotegravir 200 MG/ML Injection (RxCUI 2594978)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2594978 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2594978

Official name2 ML cabotegravir 200 MG/ML Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known ascabotegravir 400 MG per 2 ML Injection; cabotegravir 400 MG in 2 ML Extended Release Injection

FDA products mapped3

Package NDCs mapped3

Reported Medicaid activity (SDUD)57,556 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cabotegravir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It can actually be both, depending on the situation. If you already have HIV and your virus is under control on your current treatment, Vocabria tablets (taken with Edurant) serve...
What exactly is Vocabria used for — is it a treatment or a prevention drug?
This is a really important safety step. Cabotegravir on its own is not a complete HIV treatment — it only blocks one step the virus uses to replicate. If HIV somehow got into your...
Why do I have to keep getting HIV tested if I'm using this for PrEP?

📖 Read our full Cabotegravir guide →

🕸️ Concept Web — How 2 ML cabotegravir 200 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 2 ML cabotegravir 200 MG/ML Injection RxCUI 2594978 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Cabotegravir 2475077 IN
Dose forms 4

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Cabotegravir Injection 2588076 SCDF
- Cabotegravir Injectable Product 2475408 SCDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 1

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Cabotegravir 200 MG/ML 2475407 SCDC
Packs 2

Fixed collections of drugs packaged and sold together, like dose packs.
- {1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 400 MG / 600 MG] 2475418 BPCK
- {1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack 2475417 GPCK

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack GPCK · 2475417
Cabotegravir 200 MG/ML SCDC · 2475407
Cabotegravir Injection SCDF · 2588076
Cabotegravir Injectable Product SCDG · 2475408

Brand-Name Concepts

{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 400 MG / 600 MG] BPCK · 2475418

📦 FDA Products & Package NDCs

3 products · 3 package NDCs

3 package NDCs map to RxCUI 2594978 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
49702-0240-15	1 KIT in 1 CARTON (49702-240-15) * 3 mL in 1 VIAL (49702-2...	Cabenuva	ViiV Healthcare Company	2021-01-21
49702-0253-15	1 KIT in 1 CARTON (49702-253-15) * 2 mL in 1 VIAL (49702-2...	Cabenuva	ViiV Healthcare Company	2021-01-21
49702-0266-63	1 KIT in 1 CARTON (49702-266-63) * 3 mL in 1 VIAL (49702-2...	Cabenuva	ViiV Healthcare Company	2025-01-21

Observed labelers: ViiV Healthcare Company (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J0741	Inj, cabote rilpivir 2mg 3mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.